Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients
Abstract Purpose This study was designed to investigate the efficacy and safety of immune checkpoint inhibitors (ICIs)-based therapy in proficient mismatch repair (pMMR)/non-microsatellite instability-high (non-MSI-H) metastatic colorectal cancer (mCRC). Methods Electronic databases were screened to...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-09-01
|
| Series: | BMC Immunology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12865-023-00564-1 |
| _version_ | 1797577107406061568 |
|---|---|
| author | Qing Wu Ziming Wang Yang Luo Xianhe Xie |
| author_facet | Qing Wu Ziming Wang Yang Luo Xianhe Xie |
| author_sort | Qing Wu |
| collection | DOAJ |
| description | Abstract Purpose This study was designed to investigate the efficacy and safety of immune checkpoint inhibitors (ICIs)-based therapy in proficient mismatch repair (pMMR)/non-microsatellite instability-high (non-MSI-H) metastatic colorectal cancer (mCRC). Methods Electronic databases were screened to identify relevant trials. The primary endpoints were pooled objective response rate (ORR) and disease control rate (DCR). Stratified analysis was accomplished on ICIs-based regimens, treatment lines and RAS status. Results Totally, 1723 mCRC patients from 39 cohorts were included. The pooled ORR, DCR, 12-month overall survival (OS) rate and 6-month progression-free survival (PFS) rate of ICIs-based therapy in pMMR/non-MSI-H mCRC were 8.5% (95% CI: 4.4%-13.5%), 48.2% (95% CI: 37.8%-58.6%), 52.3% (95% CI: 46.4%-58.1%) and 32.8% (95% CI: 23.5%-42.7%) respectively. As a whole, no significantly differences were shown between ICIs-based and non-ICIs-based therapy for pMMR/non-MSI-H mCRC in terms of both PFS (HR = 1.0, 95% CI: 0.9–1.1, P = 0.91) and OS (HR = 1.0, 95% CI: 0.9–1.2, P = 0.51). It was worth noting that the addition of ICIs to anti-vascular endothelial growth factor (VEGF) agent plus chemotherapy displayed excellent efficacy in pMMR/non-MSI-H mCRC (ORR = 42.4%, 95% CI: 10.0%-78.6%; DCR = 92.0%, 95% CI: 68.3%-100.0%; 12-month OS rate = 71.4%, 95% CI: 50.0%-89.1%; 6-month PFS rate = 55.2%, 95% CI: 24.8%-83.8%; and PFS (compared with non-ICIs-based therapy): HR = 0.9, 95% CI: 0.8–1.0, P = 0.02), especially served as first-line therapy (ORR = 74.2%, 95% CI: 61.4%-85.4%; DCR = 98.7%, 95% CI: 92.0%-100.0%); and without additional treatment related adverse events (TRAEs) were observed. Conclusions ICIs-based combination therapy, especially the addition of ICIs to first-line anti-VEGF agent plus chemotherapy, is promising in pMMR/non-MSI-H mCRC with good efficacy and controllable toxicity. |
| first_indexed | 2024-03-10T22:03:21Z |
| format | Article |
| id | doaj.art-6f653b40304b48deb2d030d662cf097f |
| institution | Directory Open Access Journal |
| issn | 1471-2172 |
| language | English |
| last_indexed | 2024-03-10T22:03:21Z |
| publishDate | 2023-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Immunology |
| spelling | doaj.art-6f653b40304b48deb2d030d662cf097f2023-11-19T12:52:05ZengBMCBMC Immunology1471-21722023-09-0124111510.1186/s12865-023-00564-1Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patientsQing Wu0Ziming Wang1Yang Luo2Xianhe Xie3Department of Oncology, Molecular Oncology Research Institute, The First Affiliated Hospital of Fujian Medical UniversityDepartment of Oncology, Molecular Oncology Research Institute, The First Affiliated Hospital of Fujian Medical UniversityDepartment of Oncology, Molecular Oncology Research Institute, The First Affiliated Hospital of Fujian Medical UniversityDepartment of Oncology, Molecular Oncology Research Institute, The First Affiliated Hospital of Fujian Medical UniversityAbstract Purpose This study was designed to investigate the efficacy and safety of immune checkpoint inhibitors (ICIs)-based therapy in proficient mismatch repair (pMMR)/non-microsatellite instability-high (non-MSI-H) metastatic colorectal cancer (mCRC). Methods Electronic databases were screened to identify relevant trials. The primary endpoints were pooled objective response rate (ORR) and disease control rate (DCR). Stratified analysis was accomplished on ICIs-based regimens, treatment lines and RAS status. Results Totally, 1723 mCRC patients from 39 cohorts were included. The pooled ORR, DCR, 12-month overall survival (OS) rate and 6-month progression-free survival (PFS) rate of ICIs-based therapy in pMMR/non-MSI-H mCRC were 8.5% (95% CI: 4.4%-13.5%), 48.2% (95% CI: 37.8%-58.6%), 52.3% (95% CI: 46.4%-58.1%) and 32.8% (95% CI: 23.5%-42.7%) respectively. As a whole, no significantly differences were shown between ICIs-based and non-ICIs-based therapy for pMMR/non-MSI-H mCRC in terms of both PFS (HR = 1.0, 95% CI: 0.9–1.1, P = 0.91) and OS (HR = 1.0, 95% CI: 0.9–1.2, P = 0.51). It was worth noting that the addition of ICIs to anti-vascular endothelial growth factor (VEGF) agent plus chemotherapy displayed excellent efficacy in pMMR/non-MSI-H mCRC (ORR = 42.4%, 95% CI: 10.0%-78.6%; DCR = 92.0%, 95% CI: 68.3%-100.0%; 12-month OS rate = 71.4%, 95% CI: 50.0%-89.1%; 6-month PFS rate = 55.2%, 95% CI: 24.8%-83.8%; and PFS (compared with non-ICIs-based therapy): HR = 0.9, 95% CI: 0.8–1.0, P = 0.02), especially served as first-line therapy (ORR = 74.2%, 95% CI: 61.4%-85.4%; DCR = 98.7%, 95% CI: 92.0%-100.0%); and without additional treatment related adverse events (TRAEs) were observed. Conclusions ICIs-based combination therapy, especially the addition of ICIs to first-line anti-VEGF agent plus chemotherapy, is promising in pMMR/non-MSI-H mCRC with good efficacy and controllable toxicity.https://doi.org/10.1186/s12865-023-00564-1Immune checkpoint inhibitorspMMRNon-MSI-HColorectal cancerEfficacySafety |
| spellingShingle | Qing Wu Ziming Wang Yang Luo Xianhe Xie Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients BMC Immunology Immune checkpoint inhibitors pMMR Non-MSI-H Colorectal cancer Efficacy Safety |
| title | Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients |
| title_full | Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients |
| title_fullStr | Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients |
| title_full_unstemmed | Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients |
| title_short | Efficacy and safety of immune checkpoint inhibitors in Proficient Mismatch Repair (pMMR)/ Non-Microsatellite Instability-High (non-MSI-H) metastatic colorectal cancer: a study based on 39 cohorts incorporating 1723 patients |
| title_sort | efficacy and safety of immune checkpoint inhibitors in proficient mismatch repair pmmr non microsatellite instability high non msi h metastatic colorectal cancer a study based on 39 cohorts incorporating 1723 patients |
| topic | Immune checkpoint inhibitors pMMR Non-MSI-H Colorectal cancer Efficacy Safety |
| url | https://doi.org/10.1186/s12865-023-00564-1 |
| work_keys_str_mv | AT qingwu efficacyandsafetyofimmunecheckpointinhibitorsinproficientmismatchrepairpmmrnonmicrosatelliteinstabilityhighnonmsihmetastaticcolorectalcancerastudybasedon39cohortsincorporating1723patients AT zimingwang efficacyandsafetyofimmunecheckpointinhibitorsinproficientmismatchrepairpmmrnonmicrosatelliteinstabilityhighnonmsihmetastaticcolorectalcancerastudybasedon39cohortsincorporating1723patients AT yangluo efficacyandsafetyofimmunecheckpointinhibitorsinproficientmismatchrepairpmmrnonmicrosatelliteinstabilityhighnonmsihmetastaticcolorectalcancerastudybasedon39cohortsincorporating1723patients AT xianhexie efficacyandsafetyofimmunecheckpointinhibitorsinproficientmismatchrepairpmmrnonmicrosatelliteinstabilityhighnonmsihmetastaticcolorectalcancerastudybasedon39cohortsincorporating1723patients |